The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125383402 12538340 2 F 20160809 20160707 20160909 EXP JP-AMGEN-JPNCT2016088301 AMGEN 0.00 F Y 59.30000 KG 20160909 MD JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125383402 12538340 1 PS panitumumab PANITUMUMAB 1 Intravenous drip 350 MG, Q2WK Y 125147 350 MG SOLUTION FOR INJECTION QOW
125383402 12538340 2 SS panitumumab PANITUMUMAB 1 Intravenous drip 350 MG, Q2WK Y 125147 350 MG SOLUTION FOR INJECTION QOW
125383402 12538340 3 SS panitumumab PANITUMUMAB 1 Intravenous drip 350 MG, Q2WK Y 125147 350 MG SOLUTION FOR INJECTION QOW
125383402 12538340 4 SS panitumumab PANITUMUMAB 1 Intravenous drip 4.8 MG/KG, Q2WK Y 125147 4.8 MG/KG SOLUTION FOR INJECTION QOW
125383402 12538340 5 SS panitumumab PANITUMUMAB 1 Intravenous drip 4.8 MG/KG, Q2WK Y 125147 4.8 MG/KG SOLUTION FOR INJECTION QOW
125383402 12538340 6 C OXALIPLATIN. OXALIPLATIN 1 Intravenous drip 130 MG, Q2WEEKS U 0 130 MG QOW
125383402 12538340 7 C OXALIPLATIN. OXALIPLATIN 1 Intravenous drip 65 MG/M2, Q2WEEKS U 0 65 MG/M**2 QOW
125383402 12538340 8 C CALCIUM LEVOFOLINATE LEVOLEUCOVORIN CALCIUM 1 Intravenous drip 300 MG, Q2WEEKS U 0 300 MG QOW
125383402 12538340 9 C CALCIUM LEVOFOLINATE LEVOLEUCOVORIN CALCIUM 1 Intravenous drip UNK UNK, Q2WEEKS U 0 QOW
125383402 12538340 10 C 5-FU /00098801/ FLUOROURACIL 1 Intravenous bolus 600 MG, Q2WEEKS U 0 600 MG QOW
125383402 12538340 11 C 5-FU /00098801/ FLUOROURACIL 1 Intravenous drip 3800 MG, Q2WEEKS U 0 3800 MG QOW

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125383402 12538340 1 Colon cancer
125383402 12538340 6 Colon cancer
125383402 12538340 8 Colon cancer
125383402 12538340 10 Colon cancer

Outcome of event

Event ID CASEID OUTC COD
125383402 12538340 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125383402 12538340 Constipation
125383402 12538340 Dermatitis acneiform
125383402 12538340 Diarrhoea
125383402 12538340 Dry skin
125383402 12538340 Dysgeusia
125383402 12538340 Erythema multiforme
125383402 12538340 Headache
125383402 12538340 Oedema peripheral
125383402 12538340 Pain
125383402 12538340 Paronychia
125383402 12538340 Peripheral sensory neuropathy
125383402 12538340 Proteinuria
125383402 12538340 Pruritus
125383402 12538340 Pyrexia
125383402 12538340 Stomatitis

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125383402 12538340 1 20151210 20151225 0
125383402 12538340 2 20160126 20160209 0
125383402 12538340 3 20160308 20160308 0
125383402 12538340 4 20160405 20160419 0
125383402 12538340 5 20160520 20160708 0
125383402 12538340 6 20151210 20160419 0
125383402 12538340 7 20160506 20160602 0
125383402 12538340 8 20151210 20160419 0
125383402 12538340 9 20160506 20160708 0
125383402 12538340 10 20151210 0
125383402 12538340 11 20151210 20160708 0